Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.

Antiviral therapy - 1 Jan 2008

Rodriguez-Frias Francisco, Jardi Rosendo, Schaper Melanie, Buti Maria, Ferrer-Costa Carles, Tabernero David, Homs Maria, Esteban Rafael

Abstract excerpt

BACKGROUND: HBV variants rtA181V/T, rtN236T and rtl233V, which confer resistance to adefovir dipivoxil (ADV), are not detected in many non-responding patients. Virological characteristics useful for predicting response have not been clearly elucidated. We determined pretreatment virological markers to predict non-response and possible emergence of new variants during therapy. METHODS: This longitudinal study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Share to Predictive Value of Tests

Share to RNA-Directed DNA Polymerase

Source

Identifiers

PMID: 19195324

Genes

PVR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.PMID 19195324Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.Semantic proximity Read ↗

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response.Semantic proximity Read ↗

Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine.Semantic proximity Read ↗

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Virological response to adefovir monotherapy and the risk of adefovir resistance.Semantic proximity Read ↗

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Semantic proximity Read ↗

Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.Semantic proximity Read ↗

Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.